Inhibition of Fosfomycin Resistance Protein FosA by Phosphonoformate (Foscarnet) in Multidrug-Resistant Gram-Negative Pathogens
- PMID: 28993329
- PMCID: PMC5700359
- DOI: 10.1128/AAC.01424-17
Inhibition of Fosfomycin Resistance Protein FosA by Phosphonoformate (Foscarnet) in Multidrug-Resistant Gram-Negative Pathogens
Abstract
FosA proteins confer fosfomycin resistance to Gram-negative pathogens via glutathione-mediated modification of the antibiotic. In this study, we assessed whether inhibition of FosA by sodium phosphonoformate (PPF) (foscarnet), a clinically approved antiviral agent, would reverse fosfomycin resistance in representative Gram-negative pathogens. The inhibitory activity of PPF against purified recombinant FosA from Escherichia coli (FosA3), Klebsiella pneumoniae (FosAKP), Enterobacter cloacae (FosAEC), and Pseudomonas aeruginosa (FosAPA) was determined by steady-state kinetic measurements. The antibacterial activity of PPF against FosA in clinical strains of these species was evaluated by susceptibility testing and time-kill assays. PPF increased the Michaelis constant (Km ) for fosfomycin in a dose-dependent manner, without affecting the maximum rate (Vmax) of the reaction, for all four FosA enzymes tested, indicating a competitive mechanism of inhibition. Inhibitory constant (Ki ) values were 22.6, 35.8, 24.4, and 56.3 μM for FosAKP, FosAEC, FosAPA, and FosA3, respectively. Addition of clinically achievable concentrations of PPF (∼667 μM) reduced the fosfomycin MICs by ≥4-fold among 52% of the K. pneumoniae, E. cloacae, and P. aeruginosa clinical strains tested and led to a bacteriostatic or bactericidal effect in time-kill assays among representative strains. PPF inhibits FosA activity across Gram-negative species and can potentiate fosfomycin activity against the majority of strains with chromosomally encoded fosA These data suggest that PPF may be repurposed as an adjuvant for fosfomycin to treat infections caused by some FosA-producing, multidrug-resistant, Gram-negative pathogens.
Keywords: Gram negative; fosfomycin; glutathione S-transferase; phosphonoformate.
Copyright © 2017 American Society for Microbiology.
Figures


Similar articles
-
Structure and Dynamics of FosA-Mediated Fosfomycin Resistance in Klebsiella pneumoniae and Escherichia coli.Antimicrob Agents Chemother. 2017 Oct 24;61(11):e01572-17. doi: 10.1128/AAC.01572-17. Print 2017 Nov. Antimicrob Agents Chemother. 2017. PMID: 28874374 Free PMC article.
-
Glutathione-S-transferase FosA6 of Klebsiella pneumoniae origin conferring fosfomycin resistance in ESBL-producing Escherichia coli.J Antimicrob Chemother. 2016 Sep;71(9):2460-5. doi: 10.1093/jac/dkw177. Epub 2016 Jun 3. J Antimicrob Chemother. 2016. PMID: 27261267 Free PMC article.
-
Small-Molecule Inhibitor of FosA Expands Fosfomycin Activity to Multidrug-Resistant Gram-Negative Pathogens.Antimicrob Agents Chemother. 2019 Feb 26;63(3):e01524-18. doi: 10.1128/AAC.01524-18. Print 2019 Mar. Antimicrob Agents Chemother. 2019. PMID: 30642934 Free PMC article.
-
Resistance to polymyxins in Gram-negative organisms.Int J Antimicrob Agents. 2017 May;49(5):526-535. doi: 10.1016/j.ijantimicag.2016.11.029. Epub 2017 Feb 3. Int J Antimicrob Agents. 2017. PMID: 28163137 Review.
-
The revival of fosfomycin.Int J Infect Dis. 2011 Nov;15(11):e732-9. doi: 10.1016/j.ijid.2011.07.007. Epub 2011 Sep 25. Int J Infect Dis. 2011. PMID: 21945848 Review.
Cited by
-
ISEcp1-Mediated Transposition Leads to Fosfomycin and Broad-Spectrum Cephalosporin Resistance in Klebsiella pneumoniae.Antimicrob Agents Chemother. 2020 Apr 21;64(5):e00150-20. doi: 10.1128/AAC.00150-20. Print 2020 Apr 21. Antimicrob Agents Chemother. 2020. PMID: 32122889 Free PMC article.
-
Synergistic Effect of Chlorogenic Acid and Caffeic Acid with Fosfomycin on Growth Inhibition of a Resistant Listeria monocytogenes Strain.ACS Omega. 2020 Mar 23;5(13):7537-7544. doi: 10.1021/acsomega.0c00352. eCollection 2020 Apr 7. ACS Omega. 2020. PMID: 32280897 Free PMC article.
-
Synergistic Effects from Combination of Cryptotanshinone and Fosfomycin Against Fosfomycin-Susceptible and Fosfomycin-Resistant Staphylococcus aureus.Infect Drug Resist. 2020 Aug 13;13:2837-2844. doi: 10.2147/IDR.S255296. eCollection 2020. Infect Drug Resist. 2020. PMID: 32884307 Free PMC article.
-
The Role of fosA in Challenges with Fosfomycin Susceptibility Testing of Multispecies Klebsiella pneumoniae Carbapenemase-Producing Clinical Isolates.J Clin Microbiol. 2019 Sep 24;57(10):e00634-19. doi: 10.1128/JCM.00634-19. Print 2019 Oct. J Clin Microbiol. 2019. PMID: 31340992 Free PMC article.
-
Anti-hepatitis C virus drug simeprevir: a promising antimicrobial agent against MRSA.Appl Microbiol Biotechnol. 2022 Apr;106(7):2689-2702. doi: 10.1007/s00253-022-11878-2. Epub 2022 Mar 26. Appl Microbiol Biotechnol. 2022. PMID: 35338386
References
-
- Gupta K, Hooton TM, Naber KG, Wullt B, Colgan R, Miller LG, Moran GJ, Nicolle LE, Raz R, Schaeffer AJ, Soper DE. 2011. International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: a 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases. Clin Infect Dis 52:e103–e120. doi:10.1093/cid/ciq257. - DOI - PubMed
-
- Wachino J, Yamane K, Suzuki S, Kimura K, Arakawa Y. 2010. Prevalence of fosfomycin resistance among CTX-M-producing Escherichia coli clinical isolates in Japan and identification of novel plasmid-mediated fosfomycin-modifying enzymes. Antimicrob Agents Chemother 54:3061–3064. doi:10.1128/AAC.01834-09. - DOI - PMC - PubMed
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical